+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 27 Actively Recruiting clinical trials

C

Actively Recruiting

Researchers are comparing two treatment combinations for adults with advanced nonsquamous non-small cell lung cancer NSCLC that is stage IV or advanced stage IIIBC, specifically with a KRAS p.G12C mutation and no PD-L1 expression. The study evaluates progression-free survival and overall survival between participants receiving sotorasib with chemotherapy and those receiving pembrolizumab with chemotherapy. This is a phase 3, randomized, open-label study aiming to find which frontline therapy might better manage this type of lung cancer. Participants are randomly assigned to one of two groups one group receives sotorasib orally combined with carboplatin and pemetrexed chemotherapy, and the other group receives pembrolizumab given intravenously combined with the same chemotherapy agents. Treatments are given as front-line therapy for their cancer. The study measures the effects of these combinations over time, including tumor response and quality of life changes. During the study, participants will be closely monitored for progression-free survival, overall survival, and other outcomes related to tumor response and quality of life through questionnaires. Researchers will track treatment-emergent adverse events, vital signs, and lab tests to evaluate safety. The study includes follow-up assessments for up to approximately 5.5 years, allowing comprehensive evaluation of long-term outcomes and side effects. Participant involvement includes regular visits for treatment administration and assessments throughout the study period.

Age: 18Years - 100YearsAll GendersPhase 3
424 locations
C

Actively Recruiting

Researchers are comparing the effectiveness of two combinations of drugs, teclistamab with daratumumab and lenalidomide Tec-DR, and talquetamab with daratumumab and lenalidomide Tal-DR, against the combination of daratumumab, lenalidomide, and dexamethasone DRd in adults with newly diagnosed multiple myeloma who are not candidates for stem cell transplant. This Phase 3 trial focuses on evaluating treatment outcomes and survival rates over an extended period. Participants will be randomly assigned to one of three groups one receiving teclistamab by subcutaneous injection combined with daratumumab and oral lenalidomide another receiving talquetamab by subcutaneous injection combined with daratumumab and lenalidomide and the third receiving daratumumab by subcutaneous injection along with oral lenalidomide and dexamethasone, which may be given orally or intravenously. Treatments will be administered according to protocol, with close monitoring throughout the study. During the study, participants will undergo regular evaluations over up to nine years, including assessments of disease progression, survival, response to treatment, and quality of life using various questionnaires. Safety will be monitored through laboratory tests, physical exams, vital signs, electrocardiograms, and tracking of any adverse events. Researchers will also measure drug concentrations and immune responses to the study drugs. Participation may last until disease progression, death, or the end of the study period.

Age: 18Years +All GendersPhase 3
270 locations
E

Actively Recruiting

Researchers are evaluating GB-0895 as an add-on therapy for adolescents and adults with severe asthma that remains uncontrolled despite using inhaled corticosteroids and other asthma controllers. This global, multicenter, randomized, double-blind, placebo-controlled Phase 3 study aims to assess the effectiveness and safety of GB-0895 in improving asthma outcomes. Participants will receive either GB-0895 or a placebo through subcutaneous injections every six months during the treatment period. The study includes a screening and run-in phase from weeks -5 to 0, a treatment phase lasting 52 weeks, and a follow-up phase lasting from week 52 to week 90. An optional open-label extension allows continued GB-0895 treatment from week 52 through week 142. During the study, participants will undergo various assessments including lung function tests, questionnaires about asthma symptoms and quality of life, and monitoring for asthma exacerbations and adverse events. Researchers will measure outcomes such as the annual rate of asthma exacerbations and changes in lung function over 52 weeks. Safety evaluations will continue throughout treatment and follow-up. The total participation duration may extend up to nearly three years if the optional extension is chosen.

Age: 12Years - 80YearsAll GendersPhase 3
158 locations
I

Actively Recruiting

This research aims to evaluate the safety, performance, and usability of several Occlutech accessory medical devices used in heart disease treatment. These devices include the Occlutech Delivery Set ODS, Occlutech Pistol Pusher OPP, Occlutech Occlusions-Pusher OOP, and Occlutech Sizing Balloon OSB. The study is international, multicenter, non-randomized, and non-invasive, focusing on catheter-based implantation procedures for cardiac implants. The study involves physicians experienced in cardiac catheterization using these accessories during implantation procedures. Investigators complete detailed surveys to assess each devices safety, including success of implantation, adverse events during or after the procedure, user harm, and any device deficiencies. The surveys also evaluate the performance, usability, and compatibility of these accessories with other devices. Subjects receive treatment following standard clinical routines and specific instructions for use. Participants who have undergone implantation with an Occlutech accessory and cardiac implant are included. Researchers monitor safety events and assess device performance and usability over a 6-month period. Data is collected via investigator questionnaires, focusing on implantation outcomes and any related complications. The total participation duration varies depending on individual follow-up but includes at least 6 months of monitoring for safety and performance.

All AgesAll Genders
36 locations
S

Actively Recruiting

Healthy Volunteer

Low back pain LBP is a widespread musculoskeletal issue affecting people of various ages and causing significant personal, social, and healthcare burdens. The study focuses on chronic low back pain CLBP, which lasts more than 12 weeks and often leads to reduced daily activity due to fear of movement. Identifying risk factors and understanding those at risk of developing chronic LBP can help improve prevention and treatment strategies. This research aims to compare joint range of motion between individuals with low back pain and healthy people using artificial intelligence AI analysis methods. Participants in this observational study will have their joint range of motion ROM measured to assess specific movement limitations. The study includes two groups patients experiencing low back pain and healthy control participants. AI-supported analysis will be used to detect differences in joint motion ranges between these groups, aiming to improve understanding of how LBP affects physical movement. During the study, participants will undergo pain evaluations lasting about 5 minutes and joint ROM assessments lasting about 20 minutes. The researchers will collect data to analyze and compare differences between the groups. The study is open to adults aged 18 to 65 who meet eligibility criteria, and it involves no treatment but diagnostic testing. Total participant involvement includes these assessments, with results helping to identify movement patterns related to LBP.

Age: 18Years - 65YearsAll Genders
1 location
C

Actively Recruiting

Researchers are evaluating two different regulation-based programs in women aged 18 to 60 years who are overweight or obese, with a body mass index between 27.0 and 39.9 kgm. The study compares a body-based regulation approach including breathing awareness, yoga practices, auricular stimulation, and relaxation, with a mind-based regulation approach focusing on psychoeducation and cognitive-emotional awareness related to stress and emotional eating. The trial aims to assess the effects of these programs on heart rate variability, emotional eating, self-compassion, mindfulness, and body composition. Participants will be randomly assigned to one of two 8-week programs. The body-based group attends twice-weekly face-to-face sessions lasting about 60 minutes each, led by a physiotherapist. The mind-based group participates in structured psychoeducation sessions in weeks 1, 4, and 8, combined with weekly digital content and online meetings, lasting 30 to 45 minutes per week. Both programs exclude overlapping practices and are designed to target different regulation pathways. Participants will be assessed at the start and end of the 8-week intervention. Assessments include heart rate variability measured by a chest strap device, questionnaires about emotional eating, mindfulness, and self-compassion, as well as body measurements and composition. Researchers will also monitor adherence and any side effects. The main outcome is change in heart rate variability, especially RMSSD, indicating cardiac vagal regulation.

Age: 18Years - 60YearsFEMALEPhase Not Applicable
1 location
B

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the effects of a breastfeeding support program based on a client health behavior interaction model on first-time mothers confidence, attitudes, and breastfeeding problems. This randomized controlled trial aims to understand how this program influences breastfeeding self-efficacy, attitudes toward breastfeeding, and the challenges mothers face. The study is conducted among primiparous mothers between 32 and 40 weeks of pregnancy. The study involves two groups an intervention group receiving a structured support program and a control group receiving standard care. The intervention includes educational sessions during the last trimester of pregnancy, five face-to-face motivational interviews postpartum at specified intervals up to 60 days, and two additional follow-up sessions via WhatsApp video calls at 4 and 5 months after birth. The control group receives routine breastfeeding education and support provided at Family Health Centers. Participants will be assessed multiple times, starting at 32-36 weeks of gestation and continuing through various postpartum time points up to 6 months. Assessments include measuring breastfeeding self-efficacy, attitudes, and problems using structured questionnaires. Researchers will monitor these outcomes to compare changes over time between the two groups. The study also includes ongoing support and data collection through in-person sessions and digital communication to track progress and challenges.

Age: 15Years - 35YearsFEMALEPhase Not Applicable
1 location
E

Actively Recruiting

Researchers are evaluating the effectiveness of Extracorporeal Shock Wave Therapy ESWT for treating spasticity in the wrist flexor muscles flexor carpi ulnaris and flexor carpi radialis of patients who have experienced a stroke and have chronic muscle stiffness. Spasticity is a common complication after stroke that causes muscle stiffness, pain, and limits function, impacting quality of life and healthcare costs. The study aims to assess ESWTs effects using objective ultrasound techniques alongside traditional clinical scales, addressing current limitations in spasticity assessment. Participants are divided into two groups one receives conventional rehabilitation including physical therapy for 1-2 hours daily, five days a week for 12 weeks, involving exercises for range of motion, stretching, resistance, posture, balance, gait, occupational therapy, and speech therapy as needed. The other group receives the same physical therapy plus radial ESWT applied twice weekly for four weeks eight sessions total targeting the wrist flexor muscles with specific dosing parameters. During the study, participants will be assessed at baseline and at 4, 8, and 12 weeks after treatment using clinical scales like the Modified Ashworth Scale to measure spasticity, as well as ultrasound measures of muscle stiffness and quality. Additional evaluations include wrist range of motion, functional independence, upper extremity motor function, and muscle echogenicity. These assessments help monitor treatment effects and guide future standardized ESWT protocols. The total duration of participation spans 12 weeks of therapy with scheduled assessments.

Age: 35Years - 65YearsAll GendersPhase Not Applicable
1 location
S

Actively Recruiting

Breast cancer is the most common cancer among women worldwide, and one of its major complications is breast cancer-related lymphedema BCRL. This condition can develop shortly after treatment or even years later, causing swelling, heaviness, discomfort, and reduced quality of life. Researchers are investigating how intermittent pneumatic compression IPC therapy compares to manual lymph drainage MLD, both standard parts of complete decongestive therapy CDT, to better understand IPCs role in treating BCRL. The study compares three groups one receiving the full CDT including MLD plus IPC, another receiving CDT without MLD but with IPC replacing it, and a third group receiving standard CDT with MLD alone. Treatments involve sessions five times a week for three weeks, using IPC at 20-50 mmHg pressure for 40 minutes per session when included. Total session durations vary from 75 to 115 minutes depending on the group and whether IPC is used alongside or instead of MLD. Participants will be monitored before and after the treatment period with measurements of arm volume and circumference, shoulder range of motion, and quality of life assessments. Other evaluations include questionnaires on arm function, swelling, heaviness, tightness, pain, and patient satisfaction. The study aims to assess acute effects within three weeks of starting rehabilitation, with all safety and outcome data collected under medical supervision.

Age: 18Years - 65YearsFEMALEPhase Not Applicable
1 location
E

Actively Recruiting

Researchers are evaluating the effectiveness of two types of electrical stimulation, intravaginal electrical stimulation IVES and perineal electrical stimulation ES, compared to bladder training alone in women with idiopathic overactive bladder OAB. This randomized, double-blind, placebo-controlled study aims to determine which method better improves incontinence symptoms and quality of life in affected women. The trial involves 63 participants divided into three groups receiving different treatments. Participants in the first group will receive IVES along with bladder training. IVES is delivered via a vaginal probe using a device, three times a week for 20 minutes each session, over 8 weeks, totaling 24 sessions. The second group will receive perineal ES with bladder training, where surface electrodes are applied around the perianal area, also three times a week for 20 minutes per session for 8 weeks. The third group will perform bladder training alone, which includes education and exercises conducted at home, focusing on pelvic anatomy and urgency suppression strategies. Throughout the study, participants will be assessed before and after the 8-week treatment period. Researchers will measure changes in incontinence episodes, symptom severity, quality of life, anxiety and depression levels, sexual function, and pelvic floor muscle strength. Safety and side effects will also be monitored. The main outcome is improvement in the rate of incontinence episodes. Participants provide written consent and are involved in regular sessions with healthcare professionals for stimulation treatments and bladder training guidance.

Age: 18Years +FEMALEPhase Not Applicable
1 location

1-10 of 27

1